Observational analysis shows seladelpar improves GLOBE score in patients with primary biliary cholangitis, indicating potential for better transplant-free survival.
Introduction: The GLOBE score is a validated risk assessment tool used to estimate transplant-free survival (TFS) in patients (pts) with primary biliary cholangitis (PBC). Seladelpar (SEL) is a first-in-class delpar (selective PPAR-delta agonist) indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in pts who have an inadequate response to UDCA, or as a monotherapy in pts unable to tolerate UDCA.
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Zeitschrift für Gastroenterologie